Abstract

Esophageal intestinal metaplasia generally is required for a diagnosis of Barrett’s esophagus (BE) and, in clinical practice, that intestinal metaplasia is identified by the presence of goblet cells. However, if BE is defined conceptually as an esophageal metaplasia that predisposes to adenocarcinoma, then the goblet cell becomes a very imperfect marker for that condition. False-positive diagnoses of BE can result from failure to distinguish true goblet cells from pseudogoblet cells, and false-negative diagnoses can result from inadequate biopsy sampling that misses goblet cells, which often are patchy in distribution. Furthermore, evidence is accumulating that there is a gastric foveolar pathway to esophageal adenocarcinoma that can occur in the absence of goblet cells, and that might be even more common and more aggressive than the familiar intestinal dysplasia pathway.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.